This study sought to identify dual modulators that specifically target cannabinoid receptor type 2 (CB2R) and muscarinic acetylcholine receptor subtype 1 (M1R), two receptors involved in various physiological and neurological processes and frequently implicated in disorders like Alzheimer's, Parkinson's, and chronic pain. Here, CHRM1 is linked to Parkinson disease.